



โรงพยาบาลกรุงเทพ
BANGKOK HOSPITAL

Wattanosoth Tumor Registry **2010**

with **5 years** survival



โรงพยาบาลกรุงเทพ
BANGKOK HOSPITAL

2 Soi Soonvijai 7, New Petchburi Rd., Bangkok 10310
Tel. 0-2310-3000 Fax 0-2318-1546
www.bangkokhospital.com, www.wattanosoth.com

Table of Contents

Message from CEO	2
Message from Director	3
Tumor Registry 2010 : Abstract	4
Annual Tumor Registry 2010	5
<i>Distribution by Age & Sex, The 10 Leading Site of Cancer, Method of Diagnosis, Patient Category, Staging, Type of Primary Treatment, Patient Follow up, Patient Nationality</i>	
Review of Breast Cancer	14
Review of Lung Cancer	19
Review of Colorectal Cancer	24
Review of Prostate Gland Cancer	28
Review of Hepatobiliary Cancer	32
Hematologic Malignancies 2010	39
Age Distribution in All Male Cancer Number of Case	52
Age Distribution in All Female Cancer Number of Case	54
Survivals of Breast Cancer Patients	56
Survivals of Colorectal Cancer Patients	58
Survivals of Lung Cancer Patients	60

Tumor Registry Team

1. Komgrit Tanisaro, M.D.
2. Natthaphum Khanchanaporn, M.D.
3. Waraphorn Chomphu
4. Surachai Sitawarin, M.D.
5. Saengduan Chindavijak, M.D.
6. Pichet Pariyarungsi



Pictured by Natthaphum K.



Wattanosoth Tumor Registry



Message from CEO

Another year for the Tumor Registry Committee at Wattanosoth Hospital has passed with great success. Nevertheless, the Tumor Registry Committee together with the hospital's management team has incessantly made a significant positive impact in the provision of the highest quality of internationally accepted medical care service for cancer patients. Through hard-work and dedicated effort, the Team continues to further strengthen, develop, and improve the hospital's cancer program in order to make Wattanosoth, the "Home for cancer patients".

I am proud to take this opportunity to present to all of you the Tumor Registry 2010 of Wattanosoth Hospital. The annual report provides readers with substantial meaningful statistics which are enlightening for monitoring and enhancing the cancer program. The data is informative and beneficial for all who are concerned in this area. In addition, the report of 2010 also includes the survival rate of the top three malignancies which are, "Breast cancer, Colorectal cancer, and Lung cancer, respectively".

Above all, my heartfelt gratitude and appreciation go to the Tumor Registry committee and to everyone who dedicated time to deliver a professional contribution, expertise and effort to this publication.

Chatree Duangnet, M.D. FAAP, FACMQ
Chief Executive Officer
 Bangkok Hospital Medical Center
 Bangkok Dusit Medical Services Pcl.



Message from Director

To plan the most safe and precise patient care program to deal with cancer diseases, it is essential that the specialists and the multidisciplinary teams constantly study, research, and gain new information, knowledge, advanced technology, and, thus are able to provide timely evolved and safe treatment. In addition, patient education and awareness also plays an important role. The efficient delivery of knowledge and information to patients and, at the same time, enable patients accessibility to knowledge and information are, therefore, considered the crucial factors of cancer patients care program.

Having passed through the busy but productive year, the Tumor Registry Committee was committed to and continued its comprehensive tumor registry program as evidenced by the "Wattanosoth Tumor Registry 2010". The information and statistics contained in this annual report are aimed to be applied as a mechanism to improve a better quality of patient care program for those who are suffering from cancer. I am confident in saying that the Team has succeeded in its substantive evolution in making a very significant difference in the provision of medical care for "cancer patients. I would like to encourage you to review the useful content in this "Wattanosoth Tumor Registry 2010".

Herewith, I wish to extend my sincere thanks and appreciation to the Tumor Registry Committee, including the administrative and support personnel of Wattanosoth Hospital. Without their professionalism, proficiency, and dedication, the accomplishments of this report would not have been possible.

Major General Niwat Boonyuen M.D. FRCST., FICS.
Director, Wattanosoth Hospital
 Bangkok Hospital Medical Center
 Bangkok Hospitals Group

Tumor Registry 2010 : Abstract

Total new cases diagnosed malignancy at Bangkok Hospital Medical Center is 1,425 cases (excluding the hematologic malignancy). There was 2.2 percent increasing in total number as compared to 1,395 cases in year 2009. Sex ratio is 1:1 an age distribution is not changed as compared to year 2009. Patient who are between 50-69 YO are majority and accounted more than half of overall. Anyway, average age in male patients is slightly younger.

Top 5 malignancies are followings ; 1) Breast (20.49 percent) 2) Lung (12.56 percent) 3) Colorectal (12.28 percent) 4) Prostate gland (6.81 percent) and 5) Liver & Hepatobiliary (6.53 percent). The top 5 cancer trend is not different from in the past 5 year (2006-2010) collection (Breast, Colorectal, Lung, Liver and Prostate gland). Anyway, when compared to last year, overall number of cases in Liver was dropped significantly 8.82 percent. Contrast to Breast cancer, Lung cancer, Colorectal cancer and Prostate cancer which still rising in number 12.3 percent, 11.9 percent, 3.6 percent and 6.6 percent respectively.

Lung cancer is still leading cancer in male for 5 year and still constant this year. Carcinoma of the cervix is the fourth cancer female in BMC but number 7th in both sexes and dropped 11.6 percent compared to year 2009. Skin, Stomach and Head & Neck are stepping up and ranking at 6th, 9th, 10th this year.

Considering patients who received treatment at BMC, Stage I is 25 percent, Stage II is 22 percent, Stage III is 18 percent and Stage IV is 26 percent. Unknown stage (due to lack of pertinent information) trend low is low at 5 percent almost similar to last year.

Considering the primary treatments that have been done in BMC, Surgery is still the majority (28 percent) followed by Radiation therapy (14 percent) and Chemotherapy (4 percent). Chemotherapy and Targeted therapy show same trend is 5 percent. Intervention treatment is remained at 2 percent.

Patients who were diagnosed cancer at BMC tend to decide receiving treatment at BMC 27 percent (30 percent last year) and these patients decide to having primary treatment in other hospitals 13 percent (13 percent last year). Surprisingly, even patients who came from other hospitals are seeking second opinion at BMC only was significantly increased (more than one-fourth of all) but those who decided to get treatment at BMC was lower than last year.


Patients who are still alive after diagnosing or treating cancer in 2010 is 42 percents, alive without disease is 11 percent. Patient was dead with cancer as leading cause was 3 percent. Rate of lost to follow up was 1 percent.

Ratio of Thai: non-Thai patient was 3:2 in year 2010 equally to last year. The top 5 rankings are Myanmar, UAE, Bangladesh, Qatar and American respectively.

It is the first time BMC can follow the patients for 5 years and report the 5-years survival. We have shown and discussed the data of those survivors of top 3 cancers which are Breast, Lung and Colorectal in separated chapter.

WSH. ANNUAL CANCER REGISTRY 2010
DISTRIBUTION OF ALL CANCER BY AGE & SEX


Age Group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	1	0.14	0	0.00	1	0.07
10 - 14	2	0.29	1	0.14	3	0.21
15 - 19	4	0.58	0	0.00	4	0.28
20 - 24	6	0.87	7	0.95	13	0.91
25 - 29	6	0.87	10	1.36	16	1.12
30 - 34	19	2.75	23	3.13	42	2.95
35 - 39	26	3.76	48	6.54	74	5.19
40 - 44	24	3.47	65	8.86	89	6.25
45 - 49	47	6.80	95	12.94	142	9.96
50 - 54	69	9.99	118	16.08	187	13.12
55 - 59	79	11.43	109	14.85	188	13.19
60 - 64	109	15.77	78	10.63	187	13.12
65 - 69	106	15.34	50	6.81	156	10.95
70 - 74	82	11.87	50	6.81	132	9.26
75 - 79	62	8.97	39	5.31	101	7.09
80 - 84	30	4.34	25	3.41	55	3.86
85 - 89	13	1.88	7	0.95	20	1.40
90 - 94	3	0.43	7	0.95	10	0.70
95 +	3	0.43	2	0.27	5	0.35
Total	691	100.00	734	100.00	1,425	100.00




THE 10 LEADING SITE OF CANCER IN BMC 2010

Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50	Breast	1	0.14	291	39.65	292	20.49
C34	Lung	116	16.79	63	8.58	179	12.56
C18-C20	Colorectal	101	14.62	74	10.08	175	12.28
C61	Prostate gland	97	14.04	0	0.00	97	6.81
C22-C24	Liver & Hepatobiliary	67	9.70	26	3.54	93	6.53
C44	Skin	32	4.63	19	2.59	51	3.58
C53	Cervix	0	0.00	46	6.27	46	3.23
C73	Thyroid gland	17	2.46	26	3.54	43	3.02
C16	Stomach	26	3.76	16	2.18	42	2.95
C11-C14	Head & Neck	29	4.20	9	1.23	38	2.67


TOP-10 OF CANCER IN MALE 2010




TOP-10 OF CANCER ALL GENDER IN BMC 2010



TOP-10 OF CANCER IN FEMALE 2010




METHOD OF DIAGNOSIS (BOTH SEX)




** Other = Previously diagnosed as Cancer from other Hospital but no document of Pathology

STAGING (BOTH SEX)




** Non stage = Carcinoma in situ and in case of CA Brain
Unspecified stage = Incomplete staging due to Patient information is not enough

PATIENT CATEGORY OF ALL CANCER IN BMC




** Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging)
Rx = Treatment


Male



Female




STAGING (TREATMENT IN BMC)




** Non stage = Carcinoma in situ and in case of CA Brain
Unspecified stage = Incomplete staging due to Patient information is not enough

Male




Female




MANAGEMENT OF OVERALL TREATMENT

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	128	18.52	122	16.62	250	17.54
RT only	97	14.04	77	10.49	174	12.21
CT only	15	2.17	12	1.63	27	1.89
Targeted therapy	4	0.58	6	0.82	10	0.70
Hormonal therapy	1	0.14	4	0.54	5	0.35
Intervention	22	3.18	6	0.82	28	1.96
Nuclear medicine	2	0.29	3	0.41	5	0.35
Concurrent chemoradiation	19	2.75	10	1.36	29	2.04
Palliative care only	7	1.01	9	1.23	16	1.12
SUR.+RT	14	2.03	18	2.45	32	2.25
SUR.+CT	12	1.74	29	3.95	41	2.88
SUR.+T	1	0.14	0	0.00	1	0.07
SUR.+Im	4	0.58	0	0.00	4	0.28
SUR.+H	0	0.00	14	1.91	14	0.98
SUR.+N	10	1.45	8	1.09	18	1.26
SUR.+Concurrent CT-RT	5	0.72	0	0.00	5	0.35
RT+T	4	0.58	1	0.14	5	0.35
RT+CT	7	1.01	15	2.04	22	1.54
RT+H	7	1.01	3	0.41	10	0.70
CT+T	1	0.14	2	0.27	3	0.21
I+T	3	0.43	0	0.00	3	0.21
Concurrent CT-RT+RT	0	0.00	3	0.41	3	0.21
Concurrent CT-RT+CT	4	0.58	3	0.41	7	0.49
Concurrent CT-RT+RT+H	1	0.14	0	0.00	1	0.07
SUR.+RT+CT	4	0.58	19	2.59	23	1.61
SUR.+RT+H	0	0.00	6	0.82	6	0.42
SUR.+RT+I	1	0.14	1	0.14	2	0.14
SUR.+RT+T	1	0.14	0	0.00	1	0.07
SUR.+CT+T	1	0.14	3	0.41	4	0.28
SUR.+CT+H	0	0.00	5	0.68	5	0.35
RT+CT+T	2	0.29	2	0.27	4	0.28
RT+CT+H	0	0.00	2	0.27	2	0.14
SUR.+RT+CT+H	0	0.00	4	0.54	4	0.28
SUR.+CT+T+I	1	0.14	1	0.14	2	0.14
SUR.+CT+H+T	0	0.00	1	0.14	1	0.07
Investigation	101	14.62	120	16.35	221	15.51
Supportive	9	1.30	6	0.82	15	1.05
PET/CT	97	14.04	75	10.22	172	12.07
Bone scan	21	3.04	23	3.13	44	3.09
Follow up	1	0.14	8	1.09	9	0.63
2 nd Opinion	84	12.16	113	15.40	197	13.82
Total	691	100.00	734	100.00	1,425	100.00


TYPE OF PRIMARY TREATMENT (BOTH SEX)



REFERRING HOSPITAL




PATIENT FOLLOW UP




** AWD = Alive with disease
 AOD = Alive without disease
 DWD = Dead with disease
 Loss F/U = Not attended
 No F/U = Intend not to continue diagnosis or treatment at BMC

PATIENT NATIONALITY

TOTAL NATIONALITY



FOREIGN NATIONALITY




Wattanosoth Tumor Registry

BREAST CANCER PATHOLOGY ACCORDING OF BREAST CANCER

Tumor site	Number
C50.0 Nipple	1
C50.1 Central portion of breast	0
C50.2 Upper-inner quadrant of breast	18
C50.3 Lower-inner quadrant of breast	16
C50.4 Upper-outer quadrant of breast	80
C50.5 Lower-outer quadrant of breast	12
C50.6 Axillary tail of breast	0
C50.8 Overlapping lesion of breast	1
C50.9 Breast, NOS	164
Total	292

Pathology Report	Number
M8000/3 Malignant neoplasm	72
M8050/3 Papillary carcinoma	2
M8201/3 Cribriform carcinoma, NOS	2
M8246/3 Neuroendocrine carcinoma	1
M8480/3 Mucinous carcinoma	3
M8500/3 Invasive ductal carcinoma	194
M8510/3 Medullary carcinoma	1
M8513/3 Atypical medullary carcinoma	1
M8520/3 Lobular carcinoma	12
M8522/3 Invasive ductal and lobular carcinoma	2
M8523/3 Invasive ductal and mucinous carcinoma	1
M9020/3 Malignant phyllodes tumor	1
Total	292

AGE




METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Female	
	Number	Percent
Biochemical	0	0.00
Other	15	10.87
Cytology	0	0.00
Histology	123	89.13
Imaging	0	0.00
Total	138	100.00

** Other = Previously diagnosed as Breast cancer from other Hospital but no document of Pathology

STAGING (TREATMENT IN BMC)




** Unspecified stage = Cannot staging in Breast cancer due to Patient information is not enough

TYPE OF TREATMENT (IN BMC ONLY)

Type of treatment	Female	
	Number	Percent
SUR. only	31	22.46
RT only	30	21.74
CT only	2	1.45
Palliative care only	1	0.72
Hormonal therapy	3	2.17
SUR.+RT	5	3.62
SUR.+CT	15	10.87
SUR.+H	9	6.52
RT+CT	4	2.90
RT+H	1	0.72
SUR.+RT+CT	16	11.59
SUR.+RT+H	6	4.35
SUR.+CT+H	2	1.45
SUR.+CT+T	1	0.72
RT+CT+T	2	1.45
RT+CT+H	4	2.90
SUR.+RT+CT+H	4	2.90
SUR.+CT+H+T	1	0.72
Concurrent CT-RT+RT+H	1	0.72
Total	138	100.00

** SUR. = Surgery
 RT = External radiation therapy
 CT = Chemotherapy
 H (Hormone) = Hormonal therapy
 T = Targeted therapy

FOLLOW UP STATUS




** AWD = Alive with disease
 AOD = Alive without disease
 DWD = Dead with disease
 No F/U = Intend not to continue diagnosis or treatment at BMC

**LUNG CANCER
 PATHOLOGY ACCORDING OF LUNG CANCER**

Tumor site	Number
C34.0 Main bronchus	2
C34.1 Upper lobe, lung	58
C34.2 Middle lobe, lung	4
C34.3 Lower lobe, lung	35
C34.8 Overlapping lesion of lung	1
C34.9 Lung, NOS	79
Total	179

Pathology Report	Number
M8000/3 Malignant neoplasm	34
M8010/3 Carcinoma, NOS	2
M8012/3 Large cell carcinoma, NOS	4
M8020/3 Carcinoma undifferentiated, NOS	4
M8021/3 Carcinoma anaplastic, NOS	1
M8041/3 Small cell carcinoma, NOS	10
M8045/3 Combined small cell carcinoma	3
M8046/3 Non small cell carcinoma	23
M8070/3 Squamous cell carcinoma, NOS	12
M8140/3 Adenocarcinoma, NOS	63
M8200/3 Adenoid cystic carcinoma	1
M8240/3 Carcinoid tumor, NOS	1
M8246/3 Neuroendocrine carcinoma, NOS	1
M8250/3 Bronchiolo-aveolar adenocarcinoma, NOS	15
M8260/3 Papillary adenocarcinoma, NOS	2
M8480/3 Mucinous adenocarcinoma	2
M8860/3 Malignant round cell tumor	1
Total	179

AGE & SEX




METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	3	5.45	5	15.15	8	9.09
Cytology	4	7.27	1	3.03	5	5.68
Histology	43	78.18	27	81.82	70	79.55
Imaging	5	9.09	0	0.00	5	5.68
Total	55	100.00	33	100.00	88	100.00

** Other = Previously diagnosed as Lung cancer from other Hospital but no document of Pathology

STAGING (TREATMENT IN BMC)




** Unspecified stage = Cannot staging in Lung cancer due to patient information is not enough

TYPE OF TREATMENT (IN BMC ONLY)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	4	7.27	6	18.18	10	11.36
RT only	27	49.09	9	27.27	36	40.91
CT only	4	7.27	4	12.12	8	9.09
Targeted therapy	3	5.45	6	18.18	9	10.23
Concurrent CT-RT	4	7.27	1	3.03	5	5.68
SUR.+RT	1	1.82	0	0.00	1	1.14
SUR.+CT	1	1.82	1	3.03	2	2.27
CT+T	0	0.00	1	3.03	1	1.14
RT+T	4	7.27	1	3.03	5	5.68
RT+CT	4	7.27	3	9.09	7	7.95
RT+Concurrent CT-RT	0	0.00	1	3.03	1	1.14
SUR.+RT+CT	1	1.82	0	0.00	1	1.14
RT+CT+T	2	3.64	0	0.00	2	2.27
Total	55	100.00	33	100.00	88	100.00

** SUR. = Surgery
 RT = External radiation therapy
 CT = Chemotherapy
 T = Targeted therapy

FOLLOW UP STATUS




** AWD = Alive with disease
 AOD = Alive without disease
 DWD = Dead with disease
 Loss F/U = Not attended
 No F/U = Intend not to continue diagnosis or treatment at BMC

**COLORECTAL CANCER
PATHOLOGY ACCORDING OF COLORECTAL CANCER**

Tumor site		Number
C18.0	Cecum colon	7
C18.1	Appendix	2
C18.2	Ascending colon	8
C18.3	Hepatic flexure of colon	4
C18.4	Transverse colon	2
C18.5	Splenic flexure of colon	3
C18.6	Descending colon	6
C18.7	Sigmoid colon	44
C18.9	Colon, NOS	27
C19.9	Rectosigmoid colon	17
C20.9	Rectum	55
Total		175

Pathology Report		Number
M8000/3	Malignant neoplasm	49
M8140/3	Adenocarcinoma	104
M8240/3	Carcinoid tumor	2
M8246/3	Neuroendocrine carcinoma	2
M8480/3	Mucinous adenocarcinoma	9
M8481/3	Mucin producing adenocarcinoma	4
M8490/3	Adenocarcinoma signet ring cell type	5
Total		175

AGE & SEX




METHOD OF DIAGNOSIS (TREATMENT IN BMC)


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	0	0.00	2	6.06	2	2.53
Cytology	0	0.00	0	0.00	0	0.00
Histology	46	100.00	31	93.94	77	97.47
Imaging	0	0.00	0	0.00	0	0.00
Total	46	100.00	33	100.00	79	100.00

** Other = Previously diagnosed as Colorectal cancer from other Hospital but no document of Pathology

STAGING (TREATMENT IN BMC)



FOLLOW UP STATUS



TYPE OF TREATMENT (IN BMC ONLY)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	29	63.04	20	60.61	49	62.03
RT only	2	4.35	2	6.06	4	5.06
CT only	3	6.52	1	3.03	4	5.06
Intervention	0	0.00	1	3.03	1	1.27
Concurrent CT-RT	2	4.35	2	6.06	4	5.06
Palliative care only	0	0.00	1	3.03	1	1.27
SUR.+RT	0	0.00	1	3.03	1	1.27
SUR.+CT	5	10.87	4	12.12	9	11.39
SUR.+Concurrent CT-RT	2	4.35	0	0.00	2	2.53
SUR.+RT+CT	1	2.17	0	0.00	1	1.27
SUR.+CT+T	1	2.17	0	0.00	1	1.27
SUR.+CT+T+I	1	2.17	1	3.03	2	2.53
Total	46	100.00	33	100.00	79	100.00

** SUR. = Surgery
 RT = External radiation therapy
 CT = Chemotherapy
 T = Targeted therapy


** AWD = Alive with disease
 AOD = Alive without disease
 DWD = Dead with disease
 DOD = Dead other disease
 Loss F/U = Not attended
 No F/U = Intend not to continue diagnosis or treatment at BMC

**PROSTATE GLAND CANCER
PATHOLOGY ACCORDING OF PROSTATE GLAND CANCER**

Tumor site		Number
C61.9	Prostate gland	97

Pathology Report		Number
M8000/3	Malignant neoplasm	27
M8120/3	Transitional cell carcinoma, NOS	2
M8140/3	Adenocarcinoma, NOS	66
M8480/3	Mucinous adenocarcinoma	1
M8550/3	Acinar cell carcinoma	1
Total		97

AGE




METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Male	
	Number	Percent
Biochemical	0	0.00
Other	9	19.15
Cytology	38	80.85
Histology	0	0.00
Imaging	0	0.00
Total	47	100.00

** Other = Previously diagnosed as Prostate gland cancer from other Hospital but no document of Pathology

STAGING (TREATMENT IN BMC)




** Unspecified stage = Incomplete staging due to Patient is not enough

TYPE OF TREATMENT (IN BMC ONLY)

Type of treatment	Number	Percent
SUR. only	16	34.04
RT only	18	38.30
Brachytherapy	5	10.64
Hormone	1	2.13
SUR.+RT	1	2.13
RT+H	6	12.77
Total	47	100.00

** SUR. = Surgery
 RT = External radiation therapy
 H (Hormone) = Hormonal therapy

FOLLOW UP STATUS




** AWD = Alive with disease
 AOD = Alive without disease
 DWD = Dead with disease
 DOD = Dead other disease
 Loss F/U = Not attended
 No F/U = Intend not to continue diagnosis or treatment at BMC

**HEPATOBIILIARY CANCER
PATHOLOGY ACCORDING OF HEPATOBIILIARY CANCER**


Tumor site		Number
C22.0	Liver	69
C22.1	Liver (Pathology is M8160/3)	10
C23.9	Gall bladder	4
C24.0	Extrahepatic bile duct	3
C24.1	Ampullar of vater	7
Total		93

Pathology Report		Number
M8000/3	Malignant neoplasm	57
M8010/3	Carcinoma, NOS	1
M8020/3	Undifferentiated carcinoma	1
M8140/3	Adenocarcinoma, NOS	11
M8160/3	Cholangiocarcinoma	5
M8162/3	Adenocarcinoma (Klatskin's Tumor)	1
M8170/3	Hepatocellular carcinoma, NOS	16
M8260/3	Papillary adenocarcinoma	1
Total		93

PATHOLOGY REPORT OF HEPATOBIILIARY CANCER





AGE & SEX





METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	8	19.51	1	9.09	9	17.31
Other	3	7.32	0	0.00	3	5.77
Cytology	0	0.00	0	0.00	0	0.00
Histology	17	41.46	5	45.45	22	42.31
Imaging	13	31.71	5	45.45	18	34.62
Total	41	100.00	11	100.00	52	100.00



STAGING (TREATMENT IN BMC)



** Unspecified stage = Incomplete staging due to Patient information is not enough

TYPE OF TREATMENT (IN BMC ONLY)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	5	12.20	4	36.36	9	17.31
RT only	5	12.20	0	0.00	5	9.62
Intervention	22	53.66	5	45.45	27	51.92
Concurrent CT-RT	1	2.44	0	0.00	1	1.92
Palliative care	3	7.32	1	9.09	4	7.69
SUR.+CT	0	0.00	1	9.09	1	1.92
SUR.+T	1	2.44	0	0.00	1	1.92
SUR.+RT+I	1	2.44	0	0.00	1	1.92
I +Targeted therapy	3	7.32	0	0.00	3	5.77
Total	41	100.00	11	100.00	52	100.00


** SUR. = Surgery
 RT = External radiation therapy
 CT = Chemotherapy
 I = Intervention
 T = Targeted therapy

TYPE OF TREATMENT IN HEPATOMA CANCER (IN BMC ONLY)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	1	2.86	1	14.29	2	4.76
RT only	5	14.29	0	0.00	5	11.90
Intervention	22	62.86	5	71.43	27	64.29
Palliative care	3	8.57	1	14.29	4	9.52
SUR.+T	1	2.86	0	0.00	1	2.38
I+Targeted therapy	3	8.57	0	0.00	3	7.14
Total	35	100.00	7	100.00	42	100.00

** SUR. = Surgery
 RT = External radiation therapy
 I = Intervention
 T = Targeted therapy


FOLLOW UP STATUS




** AWD = *Alive with disease*
 AOD = *Alive without disease*
 DWD = *Dead with disease*
 No F/U = *Intend not to continue diagnosis or treatment at BMC*

**HEMATOLOGIC MALIGNANCIES 2010
 DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY ICD-10**


Code	Disease	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C81	Hodgkin's disease	7	10.77	4	12.12	11	11.22
C82	Follicular NHL	5	7.69	4	12.12	9	9.18
C83	Diffuse NHL	27	41.54	14	42.42	41	41.84
C84	Peripheral and cutaneous T-cell lymphoma	1	1.54	2	6.06	3	3.06
C85	Other and unspecified type of NHL	9	13.85	2	6.06	11	11.22
C90	Multiple myeloma	3	4.62	2	6.06	5	5.10
C91	Lymphoid leukemia	3	4.62	2	6.06	5	5.10
C92	Myeloid leukemia	9	13.85	3	9.09	12	12.24
C96	T-cell lymphoblastic lymphoma (Other and unspecified malignant neoplasms of lymphoid)	1	1.54	0	0.00	1	1.02
Total		65	100.00	33	100.00	98	100.00



DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY AGE & SEX



DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY PATIENT CATEGORIES




** Dx = Diagnosis for cancer

Rx = Treatment

Here = Within Bangkok Hospital Medical Center

Other = Outside Bangkok Hospital Medical Center

DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY FOLLOW UP STATUS



** AWD = Alive with Disease


AOD = Alive without Disease (Remission)

DWD = Dead with Disease

Intend not to F/U = Intend not to continue diagnosis or treatment at BMC

DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY PATIENT NATIONALITY



Nationality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Thai	30	46.15	23	69.70	53	54.08
Foreign	35	53.85	10	30.30	45	45.92
Total	65	100.00	33	100.00	98	100.00



**LYMPHOMA
DISTRIBUTION OF LYMPHOMA BY PATIENT AGE & SEX**

Age Group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	1	2.00	0	0.00	1	1.32
10 - 14	2	4.00	0	0.00	2	2.63
15 - 19	2	4.00	0	0.00	2	2.63
20 - 24	4	8.00	1	3.85	5	6.58
25 - 29	1	2.00	3	11.54	4	5.26
30 - 34	2	4.00	1	3.85	3	3.95
35 - 39	4	8.00	3	11.54	7	9.21
40 - 44	5	10.00	2	7.69	7	9.21
45 - 49	4	8.00	3	11.54	7	9.21
50 - 54	2	4.00	3	11.54	5	6.58
55 - 59	3	6.00	0	0.00	3	3.95
60 - 64	7	14.00	2	7.69	9	11.84
65 - 69	4	8.00	3	11.54	7	9.21
70 - 74	3	6.00	0	0.00	3	3.95
75 - 79	4	8.00	1	3.85	5	6.58
80 - 84	0	0.00	2	7.69	2	2.63
85 - 89	2	4.00	0	0.00	2	2.63
90 - 94	0	0.00	2	7.69	2	2.63
95 +	0	0.00	0	0.00	0	0.00
Total	50	100.00	26	100.00	76	100.00


Age Group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
< 15 yr.	3	6.00	0	0.00	3	3.95
≥ 15 yr.	47	94.00	26	100.00	73	96.05
Total	50	100.00	26	100.00	76	100.00



**HISTOPATHOLOGY
DISTRIBUTION OF LYMPHOMA BY METHOD OF DIAGNOSIS (TREATMENT AT BMC)**

Conclude method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology only	10	52.63	7	70.00	17	58.62
Histopathology + Flow cytometry	1	5.26	1	10.00	2	6.90
Histopathology + Immunohistochemistry	3	15.79	0	0.00	3	10.34
Histopathology + Immunophenotypic	1	5.26	0	0.00	1	3.45
Histopathology + Flow cytometry + Chromosome	2	10.53	0	0.00	2	6.90
Histopathology + Immunohistochemistry + Chromosome	1	5.26	0	0.00	1	3.45
Histopathology + Flow cytometry + Immunohistochemistry	1	5.26	1	10.00	2	6.90
Histopathology + Flow cytometry + Peripheral blood smear	0	0.00	1	10.00	1	3.45
Total	19	100.00	10	100.00	29	100.00

DISTRIBUTION OF LYMPHOMA BY METHOD OF DIAGNOSIS (TREATMENT AT BMC)




** Unspecified stage = Incomplete staging due to Patient information is not enough

DISTRIBUTION OF LYMPHOMA BY TREATMENT (TREATMENT AT BMC)


Conclude treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR. only	1	5.26	1	10.00	2	6.90
RT only	8	42.11	1	10.00	9	31.03
Chemotherapy only	5	26.32	5	50.00	10	34.48
SUR.+CT	1	5.26	1	10.00	2	6.90
Chemotherapy+RT	2	10.53	0	0.00	2	6.90
Chemotherapy+T	2	10.53	2	20.00	4	13.79
Total	19	100.00	10	100.00	29	100.00

** CT = Chemotherapy



**MULTIPLE MYELOMA
DISTRIBUTION OF LYMPHOMA BY PATIENT AGE & SEX**

Age Group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
25 - 29	1	33.33	0	0.00	1	20.00
30 - 34	0	0.00	0	0.00	0	0.00
35 - 39	0	0.00	0	0.00	0	0.00
40 - 44	0	0.00	0	0.00	0	0.00
45 - 49	0	0.00	0	0.00	0	0.00
50 - 54	0	0.00	0	0.00	0	0.00
55 - 59	0	0.00	0	0.00	0	0.00
60 - 64	0	0.00	0	0.00	0	0.00
65 - 69	0	0.00	1	50.00	1	20.00
70 - 74	2	66.67	0	0.00	2	40.00
75 - 79	0	0.00	1	50.00	1	20.00
Total	3	100.00	2	100.00	5	100.00




DISTRIBUTION OF LYMPHOMA BY METHOD OF DIAGNOSIS (TREATMENT AT BMC)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology only	1	100.00	1	100.00	2	100.00
Total	1	100.00	1	100.00	2	100.00


DISTRIBUTION OF LYMPHOMA BY (TREATMENT AT BMC)

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	0	0.00	0	0.00	0	0.00
Stage II	0	0.00	0	0.00	0	0.00
Stage III	0	0.00	1	100.00	1	50.00
Stage IV	1	100.00	0	0.00	1	50.00
Unspecified stage	0	0.00	0	0.00	0	0.00
Total	1	100.00	1	100.00	2	100.00




DISTRIBUTION OF LYMPHOMA BY TREATMENT (TREATMENT AT BMC)

Treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Chemotherapy only	0	0.00	1	100.00	1	50.00
Radiotherapy only	1	100.00	0	0.00	1	50.00
Total	1	100.00	1	100.00	2	100.00




LEUKEMIA DISTRIBUTION OF LEUKEMIA BY PATIENT AGE & SEX

Age Group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
05 - 09	2	16.67	0	0.00	2	11.76
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	1	8.33	1	20.00	2	11.76
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	1	20.00	1	5.88
30 - 34	0	0.00	1	20.00	1	5.88
35 - 39	0	0.00	0	0.00	0	0.00
40 - 44	2	16.67	0	0.00	2	11.76
45 - 49	1	8.33	1	20.00	2	11.76
50 - 54	1	8.33	0	0.00	1	5.88
55 - 59	1	8.33	0	0.00	1	5.88
60 - 64	1	8.33	0	0.00	1	5.88
65 - 69	0	0.00	0	0.00	0	0.00
70 - 74	2	16.67	1	20.00	3	17.65
75 - 79	0	0.00	0	0.00	0	0.00
80 - 84	1	8.33	0	0.00	1	5.88
Total	12	100.00	5	100.00	17	100.00



Age Group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
< 15 yr.	2	16.67	0	0.00	2	11.76
≥ 15 yr.	10	83.33	5	100.00	15	88.24
Total	12	100.00	5	100.00	17	100.00




DISTRIBUTION OF LEUKEMIA BY METHOD OF DIAGNOSIS (TREATMENT AT BMC)

Conclude method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histology	1	20.00	0	0.00	1	16.67
Histology + Chromosome	1	20.00	0	0.00	1	16.67
Histology + Flow cytometry + Chromosome	2	40.00	1	100.00	3	50.00
Histology + Flow cytometry + Peripheral blood smear	1	20.00	0	0.00	1	16.67
Total	5	100.00	1	100.00	6	100.00

DISTRIBUTION OF LEUKEMIA BY TREATMENT (TREATMENT AT BMC)

Conclude treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Chemotherapy	2	40.00	1	100.00	3	50.00
Targeted therapy	1	20.00	0	0.00	1	16.67
Bone Marrow Transplantation	1	20.00	0	0.00	1	16.67
Conservative treatment	1	20.00	0	0.00	1	16.67
Total	5	100.00	1	100.00	6	100.00



AGE DISTRIBUTION IN ALL MALE CANCER NUMBER OF CASE

ICD-O	Primary site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.14
C01-C02	Tongue	0	0	0	0	0	0	0	0	1	1	0	3	1	1	2	0	0	0	0	0	9	1.30
C03	Gum	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	2	0.29
C04	Floor of mouth	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.14
C05	Palate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.14
C06	Other part of mouth	0	0	0	0	0	0	0	0	0	3	1	0	0	0	0	1	0	0	0	0	5	0.72
C07	Parotid gland	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0.14
C08	Salivary gland	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0.29
C09	Tonsil	0	0	0	0	0	0	0	0	1	0	2	0	3	0	0	0	0	0	0	0	6	0.87
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C11-C14	Head & neck	0	0	0	0	0	0	3	4	3	4	3	4	4	2	0	1	1	0	0	0	29	4.20
C15	Esophagus	0	0	0	0	0	0	0	0	0	1	2	2	4	5	4	4	4	1	0	1	28	4.05
C16	Stomach	0	0	0	0	1	0	1	2	1	3	3	0	5	2	5	2	1	0	0	0	26	3.76
C17	Small intestine	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	2	0.29
C18-C20	Colon & Rectum	0	0	0	0	2	0	4	3	2	5	9	13	14	19	17	5	3	4	1	0	101	14.62
C21	Anus	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0.14
C22-C24	Liver & Hepatobiliary	0	0	0	0	0	1	0	0	3	6	8	10	10	14	5	7	2	1	0	0	67	9.70
C25	Pancreas	0	0	0	0	0	0	0	1	1	3	1	2	7	2	0	2	0	0	0	0	19	2.75
C26	Other and ill-defined digestive organ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C30	Nasal cavity	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.14
C31	Accessory sinuses	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.14
C32	Larynx	0	0	0	0	0	0	0	1	0	0	1	1	4	1	1	2	3	0	0	0	14	2.03
C33-C34	Lung	0	0	0	0	0	0	1	2	1	1	17	14	24	19	13	12	6	6	0	0	116	16.79
C37	Thymus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C38	Mediastinum	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3	0.43
C40-C41	Bone	0	0	1	1	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	5	0.72



ICD-O	Primary site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C43-C44	Skin	0	0	0	0	0	1	0	1	4	4	0	4	1	6	6	0	2	1	0	1	32	4.63
C48	Retroperitoneum	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.00
C49	Connective tissue	0	0	0	1	2	0	3	3	1	0	0	0	1	1	0	2	0	0	0	0	16	2.32
C50	Breast	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0	0	0	0	0	1	0.14
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C52	Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C53	Cervix	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C54	Corpus uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C55	Uterus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C56	Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C60	Penis	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	1	0	4	0.58
C61	Prostate gland	0	0	0	0	0	0	0	0	0	1	4	13	14	21	20	17	6	0	1	0	97	14.04
C62	Testis	0	0	0	0	0	1	0	1	2	0	1	1	0	0	0	0	0	0	0	0	6	0.87
C64-C65	Urinary tract	0	1	0	0	0	0	0	3	1	2	4	4	6	1	2	3	1	0	0	0	28	4.05
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C67	Bladder	0	0	0	0	0	1	1	0	0	1	4	3	5	2	4	2	0	0	0	0	23	3.33
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye & adnexa	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C70-C71	Brain	0	0	1	2	0	0	1	1	0	6	1	1	0	0	0	0	1	0	0	0	14	2.03
C72	Spinal cord & CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	0	0	0	0	0	0	3	2	2	3	1	2	2	2	0	0	0	0	0	0	17	2.46
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C75	Other & endocrine gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C76	Other & ill-defined	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C80	Unknown primarysite	0	0	0	0	0	0	1	0	0	0	2	1	1	4	1	1	0	0	0	1	12	1.74
All ICD Group		0	1	2	4	6	6	19	26	24	47	69	79	109	106	82	62	30	13	3	3	691	100.00

AGE DISTRIBUTION IN ALL FEMALE CANCER NUMBER OF CASE

ICD-O	Primary site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C01-C02	Tongue	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0	2	0	0	0	5	0.68
C03	Gum	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.14
C04	Floor of mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C05	Palate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C06	Other part of mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.14
C07	Parotid gland	0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	0	0	0	0	0	3	0.41
C08	Salivary gland	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.14
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C11-C14	Head & neck	0	0	0	0	0	0	0	0	0	1	6	1	1	0	0	1	1	0	0	0	9	1.23
C15	Esophagus	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	1	1	0	0	0	5	0.68
C16	Stomach	0	0	0	0	0	0	2	0	4	1	1	1	2	2	1	1	1	1	0	0	16	2.18
C17	Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C18-C20	Colon & Rectum	0	0	0	0	1	0	2	2	3	3	10	15	9	5	6	11	2	3	2	0	74	10.08
C21	Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.14
C22-C24	Liver & Hepatobiliary	0	0	0	0	0	0	1	2	2	1	3	4	5	4	1	2	0	1	0	0	26	3.54
C25	Pancreas	0	0	0	0	0	0	1	0	2	2	1	1	1	1	3	2	1	0	0	0	14	1.91
C26	Other and ill-defined digestive organ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C30	Nasal cavity	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0.14
C31	Accessory sinuses	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.14
C32	Larynx	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0.14
C33-C34	Lung	0	0	0	0	0	1	2	4	9	7	10	7	6	7	4	4	0	2	0	0	63	8.58
C37	Thymus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.14
C38	Mediastinum	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0.27
C40-C41	Bone	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	0.27



ICD-O	Primary site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C43-C44	Skin	0	0	0	0	1	0	0	0	1	1	3	4	0	0	2	0	4	1	2	0	19	2.59
C48	Retroperitoneum	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	2	0.27
C49	Connective tissue	0	0	0	0	1	1	1	2	0	0	0	2	1	0	0	0	0	0	0	0	8	1.09
C50	Breast	0	0	0	0	1	0	11	19	35	48	62	42	32	13	13	9	4	0	2	0	291	39.65
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C52	Vagina	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	0	0	0	0	4	0.54
C53	Cervix	0	0	0	0	0	2	1	4	6	7	5	4	5	2	4	3	2	0	0	1	46	6.27
C54	Corpus uteri	0	0	0	0	1	0	0	0	0	2	8	8	2	2	1	4	1	0	0	0	28	3.81
C55	Uterus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C56	Ovary	0	0	0	0	0	0	0	2	3	7	3	4	2	0	2	0	1	0	0	0	25	3.41
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.14
C60	Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C61	Prostate gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C62	Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C64-C65	Urinary tract	0	0	0	0	0	1	1	0	0	1	0	0	1	1	2	1	1	0	0	1	10	1.36
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.14
C67	Bladder	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	3	0.41
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye & adnexa	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C70-C71	Brain	0	0	0	0	1	0	1	0	1	0	0	0	1	2	1	0	0	0	0	0	7	0.95
C72	Spinal cord & CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	0	0	0	0	2	4	3	5	3	2	3	1	2	1	0	0	0	0	0	0	26	3.54
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C75	Other & endocrine gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C76	Other & ill-defined	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C80	Unknown primarysite	0	0	0	0	0	0	0	1	0	0	0	1	2	1	2	0	1	0	0	0	8	1.09
D05	Ductal carcinoma in situ of breast	0	0	0	0	0	0	0	4	3	7	4	4	3	2	0	1	0	0	0	0	28	3.81
	All ICD Group	0	0	1	0	7	10	23	49	66	95	117	108	78	51	49	39	25	7	7	2	734	100.00

SURVIVALS OF BREAST CANCER PATIENTS




สรุปผลการวิเคราะห์ระยะรอดชีพของผู้ป่วยมะเร็งเต้านม

สรุป ผู้ป่วยที่ศึกษาทั้งหมด 155 ราย รวมเป็นหน่วยศึกษา 5,452 คน-เดือน มีผู้ป่วยตาย 13 ราย คิดเป็นอุบัติการณ์ 2.38 ต่อ 1,000 คน-เดือน (95% CI: 1.27 - 4.08) โอกาสที่จะอยู่รอดโดยปลอดเหตุการณ์ในระยะ 48 เดือน เท่ากับ 89.7% (95% CI: 82.7% - 93.9%)

ผู้ป่วยมะเร็งเต้านมอายุน้อยกว่าหรือเท่ากับ 50 ปี รวมเป็นหน่วยศึกษา 2,288 คน-เดือน มีอัตราการตายเท่ากับ 3.06/1,000 คน-เดือน ในขณะที่ผู้ป่วยอายุมากกว่า 50 ปี รวมเป็นหน่วยศึกษา 3,164 คน-เดือน มีอัตราการตายเท่ากับ 1.89/1,000 คน-เดือน ณ เดือนที่ 52 หลังการรักษา Survival probability ของผู้ป่วยอายุน้อยกว่าหรือเท่ากับ 50 ปี เท่ากับ 87.65% (95% CI: 75.63 ถึง 93.97) ต่ำกว่าผู้ป่วยอายุมากกว่า 50 ปี ซึ่งมีค่าเท่ากับ 91.13% (95% CI: 81.17 ถึง 95.95)

ผู้ป่วยมะเร็งเต้านมระยะสุดท้ายจะมีอัตราการรอดชีพต่ำสุด โดยพบว่าผู้ป่วยระยะดังกล่าวมีอัตราการตายสูงสุดเท่ากับ 26.94 ต่อ 1,000 คน-เดือน ในขณะที่ผู้ป่วยระยะที่ 3 ระยะที่ 2 และระยะที่ 1 มีอัตราการตายคิดเป็น 2.70, 1.78 และ 0 ต่อ 1,000 คน-เดือน ตามลำดับ

ณ เดือนที่ 52 หลังการรักษาความน่าจะเป็นในการรอดชีพ (Survival probability) ของผู้ป่วยมะเร็งเต้านมระยะสุดท้ายเท่ากับ 36.36% (95% CI: 11.73 ถึง 62.04), ผู้ป่วยมะเร็งเต้านมระยะที่ 3 เท่ากับ 88.44% (95% CI: 60.29 ถึง 97.06), ผู้ป่วยมะเร็งเต้านมระยะที่ 2 เท่ากับ 91.07% (95% CI: 74.35 ถึง 97.09) และผู้ป่วยมะเร็งเต้านมระยะที่ 1 เท่ากับ 100.0%



SURVIVALS OF COLORECTAL CANCER PATIENTS

สรุปผลการวิเคราะห์ระยะรอดชีพของผู้ป่วยมะเร็งลำไส้





สรุป ผู้ป่วยที่ศึกษาทั้งหมด 58 ราย รวมเป็นหน่วยศึกษา 1,419 คน-เดือน มีผู้ป่วยตาย 7 ราย คิดเป็นอุบัติการณ์ 4.93 ต่อ 1,000 คน-เดือน (95% CI: 1.98 - 10.16) โอกาสที่จะอยู่โดยปลอดเหตุการณ์ในระยะ 48 เดือน เท่ากับ 83.6% (95% CI: 67.6% - 92.1%)

ผู้ป่วยมะเร็งลำไส้ในเพศชาย รวมเป็นหน่วยศึกษา 748 คน-เดือน มีอัตราตายเท่ากับ 4.01/1,000 คน-เดือน ในขณะที่ผู้ป่วยในเพศหญิง รวมเป็นหน่วยศึกษา 671 คน-เดือน มีอัตราตายเท่ากับ 5.96/1,000 คน-เดือน ณ เดือนที่ 52 หลังการรักษา Survival probability ของผู้ป่วยลำไส้ในเพศชายเท่ากับ 87.31% (95% CI: 63.52 ถึง 96.02) สูงกว่าผู้ป่วยลำไส้ในเพศหญิงซึ่งมีค่าเท่ากับ 78.95% (95% CI: 51.72 ถึง 91.88)

ผู้ป่วยมะเร็งลำไส้ที่มีอายุน้อยกว่าหรือเท่ากับ 60 ปี รวมเป็นหน่วยศึกษา 530 คน-เดือน มีอัตราตายเท่ากับ 1.88/1,000 คน-เดือน ในขณะที่ผู้ป่วยมะเร็งลำไส้ที่มีอายุมากกว่า 60 ปี รวมเป็นหน่วยศึกษา 889 คน-เดือน มีอัตราตายเท่ากับ 6.75/1,000 คน-เดือน ณ เดือนที่ 52 หลังการรักษา Survival probability ของผู้ป่วยมะเร็งลำไส้ที่มีอายุน้อยกว่าหรือเท่ากับ 60 ปีเท่ากับ 95.24% (95% CI: 70.72 ถึง 99.32) ต่ำกว่าผู้ป่วยมะเร็งลำไส้ที่มีอายุมากกว่า 60 ปี ซึ่งมีค่าเท่ากับ 77.19% (95% CI: 55.05 ถึง 89.37)

ผู้ป่วยมะเร็งลำไส้ระยะสุดท้ายจะมีอัตราการรอดชีพต่ำสุด โดยพบว่าผู้ป่วยระยะดังกล่าวมีอัตราการตายสูงสุดเท่ากับ 43.48 ต่อ 1,000 คน-เดือน ในขณะที่ผู้ป่วยระยะที่ 3 ระยะที่ 2 และระยะที่ 1 มีอัตราการตายคิดเป็น 1.41, 0 และ 0 ต่อ 1,000 คน-เดือน ตามลำดับ

ณ เดือนที่ 23 หลังการรักษาความน่าจะเป็นในการรอดชีพ (Survival probability) ของผู้ป่วยมะเร็งลำไส้ระยะสุดท้ายเท่ากับ 0% ส่วนระยะที่ 3 ระยะที่ 2 และระยะที่ 1 ณ เดือนที่ 52 หลังการรักษาความน่าจะเป็นในการรอดชีพ (Survival probability) เท่ากับ 88.44% (95% CI: 60.29 ถึง 97.06), 91.07% (95% CI: 74.35 ถึง 97.09) และ 100.0% ตามลำดับ



SURVIVALS OF LUNG CANCER PATIENTS

สรุปผลการวิเคราะห์ระยะรอดชีพของผู้ป่วยมะเร็งปอด




สรุป ผู้ป่วยที่ศึกษาทั้งหมด 57 ราย รวมเป็นหน่วยศึกษา 769 คน-เดือน มีผู้ป่วยตาย 17 ราย คิดเป็นอุบัติการณ์ 22.11 ต่อ 1,000 คน-เดือน (95% CI: 12.88 - 35.39) โอกาสที่จะอยู่โดยปลอดเหตุการณ์ในระยะ 48 เดือน เท่ากับ 52.91% (95% CI: 34.65% - 68.23%)



ผู้ป่วยมะเร็งปอดในเพศชาย รวมเป็นหน่วยศึกษา 427 คน-เดือน มีอัตราตายเท่ากับ 30.45/1,000 คน-เดือน ในขณะที่ผู้ป่วยมะเร็งปอดในเพศหญิง รวมเป็นหน่วยศึกษา 342 คน-เดือน มีอัตราตายเท่ากับ 11.70/1,000 คน-เดือน ณ เดือนที่ 51 หลังการรักษา Survival probability ของผู้ป่วยมะเร็งปอดในเพศชายเท่ากับ 46.38% (95% CI: 24.13 ถึง 66.02) ต่ำกว่าผู้ป่วยมะเร็งปอดในเพศหญิงซึ่งมีค่าเท่ากับ 65.66% (95% CI: 31.77 ถึง 85.70)

ผู้ป่วยมะเร็งปอดที่มีอายุน้อยกว่าหรือเท่ากับ 60 ปี รวมเป็นหน่วยศึกษา 497 คน-เดือน มีอัตราตายเท่ากับ 14.08/1,000 คน-เดือน ในขณะที่ผู้ป่วยมะเร็งปอดที่มีอายุมากกว่า 60 ปี รวมเป็นหน่วยศึกษา 272 คน-เดือน มีอัตราตายเท่ากับ 36.76/1,000 คน-เดือน ณ เดือนที่ 52 หลังการรักษา Survival probability ของผู้ป่วยมะเร็งปอดที่มีอายุน้อยกว่าหรือเท่ากับ 60 ปี เท่ากับ 61.82% (95% CI: 35.84 ถึง 79.82) ต่ำกว่าผู้ป่วยมะเร็งปอดที่มีอายุมากกว่า 60 ปี ซึ่งมีค่าเท่ากับ 40.47% (95% CI: 15.50 ถึง 64.47)

ผู้ป่วยมะเร็งปอดระยะสุดท้ายจะมีอัตราการรอดชีพต่ำสุด โดยพบว่าผู้ป่วยระยะดังกล่าวมีอัตราการตายสูงสุดเท่ากับ 48.58 ต่อ 1,000 คน-เดือน ในขณะที่ผู้ป่วยระยะที่ 3 ระยะที่ 2 และระยะที่ 1 มีอัตราการตายคิดเป็น 7.14, 7.29 และ 6.02 ต่อ 1,000 คน-เดือน ตามลำดับ

ณ เดือนที่ 52 หลังการรักษาความน่าจะเป็นในการรอดชีพ (Survival probability) ของผู้ป่วยมะเร็งปอดระยะสุดท้าย ระยะที่ 3 ระยะที่ 2 และระยะที่ 1 เท่ากับ 33.72% (95% CI: 12.40 ถึง 56.76), 83.33% (95% CI: 27.31 ถึง 97.47), 80.0% (95% CI: 20.38 ถึง 96.92) และ 75.0% (95% CI: 12.79 ถึง 96.05) ตามลำดับ





Wattanosoth Tumor Registry

Pictured by Charnchai T.